30 October 2025

Q1 FY26 Quarterly Update

First Rest Assure® US Clinical Site Confirmed

SomnoMed Limited (ASX "SOM" or the Company), the leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), is pleased to provide its quarterly activities report for the period ended 30 September 2025 (Q1 FY26).

Q1 FY26 Highlights

- Q1 FY26 revenue of $28.7m, up 13.5% (7.0% in constant currency) versus previous corresponding period (pcp).
- The Clayton Sleep Institute has been confirmed as the first US site for the Rest Assure® clinical efficacy study.
- A second leading US clinic is expected to be announced in the coming weeks.
- Cash balance was $16.5m as at 30 September 2025.
- The Company reaffirms its FY26 guidance of:
    - Revenue of between $119m and $126m
    - EBITDA of between $10m and $12m
    - Capex of between $6m and $8m

Q1 FY26 Financial Review

Q1 FY26 revenue of $28.7m, up 13.5% (7.0% in constant currency) versus pcp, split regionally as follows:

Revenue (A$000's)	Q1 FY26 (A$000's)	Q1 FY25 (A$000's)	% Change Actual	% Change Constant Currency
Europe	15,364	13,124	+17.1%	+7.1%
North America	11,427	10,163	+12.4%	+9.2%
APAC	1,874	1,964	-4.6%	-5.0%
Total Group Revenue	**28,665**	**25,251**	**+13.5%**	**+7.0%**

Over the quarter Europe and North America both saw double digit growth compared to the same period last year. APAC demand was slightly down versus the prior corresponding period, however brand loyalty and medical referrals remain strong.

Q1 FY26 unit sales exceeded those of Q1 FY25, which benefited from the clearing of the FY24 backlog, demonstrating sustained growth momentum.

Q1 FY26 Operational Update

SomnoMed is pleased to confirm the **Clayton Sleep Institute**, a leading US sleep clinic, to conduct a clinical study to evaluate the efficacy of Rest Assure® compared with gold-standard sleep testing. Securing the involvement of this highly respected institution represents an exciting milestone in advancing the clinical validation of Rest Assure®.

SomnoMed can also confirm that the FDA has recently advised that it is fundamentally in agreement with the Company's recommended protocol for the Rest Assure® study, with some requested modifications to be followed up. The study will generate data to support an FDA submission for efficacy monitoring. If cleared, Rest Assure® would be the only oral device approved for both efficacy and compliance monitoring.

SomnoMed is in the final stages of formalising arrangements with a second highly regarded US sleep clinic, which is expected to be announced in the coming weeks.

Co-CEO's Amrita Blickstead and Karen Borg commented: *"The commitment from the Clayton Sleep Institute, a highly respected sleep research institution in the US, represents a major milestone in advancing the clinical validation of Rest Assure®. Their involvement adds significant credibility to the study and underscores the strong clinical momentum behind Rest Assure® as we progress toward commercialisation."*

---ends---

This release has been approved by the Board of SomnoMed Limited.

For further information please contact

Investor Relations: ir@somnomed.com

SomnoMed Limited - 20 Clarke St, Crows Nest, NSW, Australia 2065

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at http://www.somnomed.com.au